Silk Road Medical (NSDQ:SILK) announced today that it is voluntarily recalling additional lots of its Enroute transcarotid stent system. Enroute, which is manufactured by Cardinal Health (NYSE:CAH) subsidiary Cordis, has received a total of six product complaints between September 2020 and January 2021 involving an issue in which a tip detaches from the stent delivery system. Additionally, test […]
Silk Road Medical Inc.
Silk Road medical adds to executive team
Stroke treatment developer Silk Road Medical (NSDQ:SILK) announced that it appointed a new executive VP of R&D and COO. William Whealon joined as executive VP of research & development, effective immediately, while current CFO Lucas Buchanan will also operate as Silk Road’s COO, effective Oct. 1. Whealon has over two decades of experience in the industry, having […]
Silk Road Medical appoints chief commercial officer
Stroke treatment developer Silk Road Medical (NSDQ:SILK) announced that it promoted Andrew Davis as its new chief commercial officer. In the newly created role at the Sunnyvale, Calif.-based company, Davis is slated to oversee Silk Road Medical’s global commercialization efforts by establishing near-term priorities and setting the long-term strategic direction for the organization, according to a […]
Silk Road Medical closes allotment option
Silk Road Medical (NSDQ:SILK) announced that underwriters fully exercised and closed on additional options to purchase shares in a stock offering. The offering of more than 6.8 million shares included the exercise of the option to purchase more than 1 million additional shares at the public offering price of $39 per share. Silk Road Medical […]
COVID-19 upends medtech’s financial outlook
The uncertain times brought on by the COVID-19 pandemic have affected businesses worldwide, and several sectors of medtech industry are projecting hits to their bottom lines. A number of companies have announced decisions to withdraw financial guidance, cut hours and/or staff, among other major business decisions. Initial impacts of the global pandemic on Wall Street […]
These young medtech companies raised the most money in 2019
Medical device industry insiders may very well remember 2019 as the year that IPOs came back — but another sign that the U.S. economy has left the Great Recession far behind. Among the top investment deals in the space, half involved public offerings, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Total investments […]
Why your medtech career needs graceful exits
Erica Rogers, the CEO of hot medtech IPO Silk Road Medical (NSDQ:SILK), learned an important career lesson back in the 1990s. After more than 10 years at Boston Scientific, Rogers didn’t want to move from the West Coast to Boston to try to rise up through the company even more. As she recently related to Medsider’s […]
Silk Road Medical ups its stock offering by $31.8 million
Silk Road Medical (NSDQ:SILK) increased a stock offering it registered earlier this week to $191.8 million, according to a regulatory filing. The company’s original registration for $159 million was to fund its transcarotid artery revascularization (TCAR) technology for the treatment of stroke. The Sunnyvale, Calif.-based company is now proposing an offering of 4.8 million shares of its […]
Silk Road Medical proposes $159m stock offering
Silk Road Medical (NSDQ:SILK) has registered a $159 million stock offering to fund its transcarotid artery revascularization (TCAR) technology for the treatment of stroke, according to a regulatory filing. The Sunnyvale, Calif.-based company is proposing an offering of 4.04 million shares of its common stock at a maximum share price of $39.50 each, including 525,000 […]
Silk Road Medical touts results of carotid artery treatment study
A new study shows that transcarotid artery revascularization (TCAR) procedures significantly lowered the odds of composite in-hospital stroke, death and heart attack compared to surgical removal of plaque from the carotid artery, according to Silk Road Medical (NSDQ:SILK). The company is developing a neuroprotection and stent system called Enroute as an aid to TCAR procedures. […]
Silk Road Medical posts mixed-bag Q1
Silk Road Medical (NSDQ:SILK) yesterday posted first quarter earnings that topped sales expectations but missed on loss-per-share consensus on Wall Street. The Sunnyvale, Calif.-based company posted losses of approximately $24.2 million, or $20.12 per share, on sales of approximately $12.8 million for the three months ended March 31, seeing losses grow 346.7% while sales grew 123.7% […]
